CEO Balakrishna (Patanjali) claims Covid cure by Ayurveda | Chronicleplanet.com

Chronicleplanet.com

Best Latest News Provider

CEO Balakrishna (Patanjali) claims Covid cure by Ayurveda

2 min read

CEO Balakrishna (Patanjali) claims Covid cure by Ayurveda

Patanjali CEO Acharya Balkrishna today claimed that treatment of COVID-19 infection is possible through Ayurveda. He told news agency ANI that after taking Patanjali medicines, COVID patients recovered in 5-14 days and then tested negative. “After taking our medicine, COVID patients recovered in 5-14 days and then tested negative. So, we can say cure for COVID is possible through Ayurveda. We are performing controlled clinical trials only. In next 4-5 days, evidence and data will be released by us,” Balkrishna was quoted as saying.

The Patanjali CEO said that a team of scientists were appointed after COVID-19 outbreak to test ayurvedic medicines against COVID-19. “We appointed a team of scientists after COVID-19 outbreak. Firstly, simulation was done and compounds were identified which can fight the virus. Then, we conducted clinical case study on many positive patients and we have got 100 per cent favourable results,” he said.

As researchers across the globe race to develop a vaccine to tackle the pandemic, Acharya Balkrishna, co-founder and Chief Executive Officer (CEO) of Patanjali Ayurveda Limited, claimed that his company developed an Ayurveda medicine that has cured Covid-19 patients within a span of five to 14 days. According to a report in news agency ANI, Balkrishna on Saturday said that a trial was conducted on hundreds of Covid-19 patients and that the medicine has yielded “100% favourable results.”

“We appointed a team of scientists after the Covid-19 outbreak. First, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results,” Balkrishna said in Haridwar, according to ANI.